| S2 Table. Characteristics affecting NAC response |
|-------------------------------------------------|
|                                                  |
|                                                  |
| | Non-pCR (n=161) | pCR (n=286) | p-value |
| Age (yr)                                          |
| < 60                                              |
| 148 (91.9)                                        |
| 249 (87.1)                                        |
| 0.159                                             |
| ≥ 60                                              |
| 13 (8.1)                                          |
| 37 (12.9)                                         |
| Menopausal status                                 |
| Pre-menopause                                     |
| 111 (68.9)                                        |
| 147 (51.4)                                        |
| < 0.001                                           |
| Post-menopause                                    |
| 50 (31.1)                                         |
| 137 (48.6)                                        |
| Histology                                         |
| IDC                                               |
| 141 (87.6)                                        |
| 262 (91.6)                                        |
| 0.187                                             |
| Others                                            |
| 20 (12.4)                                         |
| 24 (8.4)                                          |
| Nuclear grade                                     |
| 2                                                 |
| 82 (50.9)                                         |
| 107 (37.4)                                        |
| 0.007                                             |
| 3                                                 |
| 79 (49.1)                                         |
| 178 (62.6)                                        |
| Hormone receptor                                  |
| ER+/PR+                                           |
| 88 (54.7)                                         |
| 53 (19.0)                                         |
| < 0.001                                           |
| ER+/PR-                                           |
| 19 (11.8)                                         |
| 52 (18.2)                                         |
| ER−/PR+                                           |
| 0                                                 |
| 3 (1.0)                                           |
| ER−/PR−                                           |
| 54 (33.5)                                         |
| 177 (61.8)                                        |
| Docetaxel RDI                                     |
| ≤ 0.85                                            |
| 8 (5.0)                                           |
| 25 (8.7)                                          |
| 0.187                                             |
| > 0.85                                            |
| 153 (95.0)                                        |
| 261 (91.3)                                        |
| Carboplatan RDI                                   |
| ≤ 0.85                                            |
| 107 (66.5)                                        |
| 192 (67.1)                                        |
| 0.917                                             |
| > 0.85                                            |
| 54 (33.5)                                         |
| 94 (32.9)                                         |

IDC, invasive ductal carcinoma; ER, estrogen receptor; NAC, neoadjuvant chemotherapy; pCR, pathologic complete response; PR, progesterone receptor; RDI, relative dose intensity.